| Pegasys (pegylated interferon α -2a) / Roche |
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet” |
|
|
| Ongoing | 3 | 200 | Europe | Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea | Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje | Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT01727323 / 2010-021337-31: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1 |
|
|
| Active, not recruiting | 3 | 109 | US, Canada, Europe | TMC435, Pegylated interferon alpha-2a, Ribavirin | Janssen Research & Development, LLC, Janssen R&D Ireland, Tibotec Pharmaceuticals | Hepatitis C Virus Genotype-1 | 08/13 | 08/13 | | |
2014-000453-37: Treatment with association of two drugs (Viread and Pegasys) in patients with hepatitis B. TRATTAMENTO CON ASSOCIAZIONE DI DUE FARMACI (VIREAD E PEGASYS) NEI PAZIENTI AFFETTI DA EPATITE B |
|
|
| Ongoing | 3 | 80 | Europe | Viread, Pegasys, Tablet, Solution for injection, Viread, Pegasys | Azienda Ospedaliera di Padova, Azienda Ospedaliera di Padova | Hepatitis B virus (HBV) EPATITE CRONICA HBV-CORRELATA, Chronic liver disease caused by hepatitis B MALATTIA EPATICA CRONICA CAUSATA DAL VIRUS DELL’EPATITE B, Diseases [C] - Virus Diseases [C02] | | | | |
2004-001622-24: Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic myeloid leukaemia |
|
|
| Ongoing | 3 | 50 | Europe | Glivec, Pegasys, Glivec (400mg), Glivec (800mg), Pegasys, Glivec (400mg), Glivec (800mg), Pegasys | Newcastle Hospital Trust | Chronic Myeloid Leukaemia (Chronic Phase) | | | | |
2006-000853-23: Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost pegylovaného interferonu alfa 2a (Pegasys) v adjuvantní léčbě rizikového primárního kožního melanomu |
|
|
| Ongoing | 3 | 252 | Europe | Pegasys 180 mikrogramů, Roferon®-A, EU/1/02/221/008, 44/396/96-C, 44/160/99-C, 44/161/99-C, 44/086/02-C, | Kožní ordinace | Chirurgicky adekvátně odstraněný a histologicky verifikovaný primární kožní melanom ve stadiu IIB až IIIB podle nové AJCC 2003 klasifikace. | | | | |
2006-006042-33: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferon |
|
|
| Ongoing | 3 | 50 | Europe | KALETRA, COPEGUS, PEGASYS, KALETRA, COPEGUS, PEGASYS | OSPEDALE S. RAFFAELE | patients affected by HIV and chronic HCV or compensated cirrhosis | | | | |
2006-005996-17: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with Ribavirin and Pegylated Interferonﾔ |
|
|
| Ongoing | 3 | 60 | Europe | KALETRA, PEGASYS, COPEGUS, KALETRA, PEGASYS, COPEGUS | OSPEDALE S. RAFFAELE | PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES | | | | |
2005-003648-70: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1. |
|
|
| Ongoing | 3 | 414 | Europe | Cedur retard, Pegasys, Copegus, Cedur retard, Pegasys, Copegus | Charité Universitätsmedizin Berlin | First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | | | | |
2006-006985-41: Estudio piloto en fase III, mutlicéntrico, aleatorizado, controlado y abierto, sobre la eficacia de Interferón Pegilado alfa-2a a dosis de 90 mcg semanal en retrasar la aparición del primer evento de descompensación hepática en pacientes con cirrosis hepática por virus C nunca descompensada y con coinfección por VIH, en los que el tratamiento estándar con Interferón Pegilado ha fracasado. Estudio IRISH. |
|
|
| Ongoing | 3 | 220 | Europe | PEGASYS (PEGINTERFERON ALFA-2A), PEGASYS (PEGINTERFERON ALFA-2A) | JOAQUIN PORTILLA | PACIENTES CON CIRROSIS HEPATICA (CH) POR VIRUS C NUNCA DESCOMPENSADA Y COINFECTADOS POR EL VIH QUE NO HAN RESPONDIDO AL TRATAMIENTO ESTANDAR CON INTERFERON PEGILADO Y RIBAVIRINA | | | | |
2008-006453-40: Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatment response and sustained viral response rates |
|
|
| Ongoing | 3 | 100 | Europe | Pegasys, Copegus, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg, Pegasys 180 mcg / 135 mcg, Copegus 200 mg / 400 mg | Karolinska University hospital Huddinge | Chronic hepatitis C infection | | | | |
2009-018146-38: Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients. |
|
|
| Ongoing | 3 | 110 | Europe | Multiferon, Pegasys, Copegus, Multiferon, Pegasys, Copegus | Swedish Orphan International AB | Hepatitis C | | | | |
2010-019501-41: A randomized study comparing two drugs: hydroxyurea and Pegylated Interferon Alfa-2a, in an open label clinical trial in two independent diseases: (1) high risk polycythaemia vera and (2) high risk essential thrombocythaemia. |
|
|
| Ongoing | 3 | 95 | Europe | peginterferon alfa-2a, Hydroxyurea, Pegasys, Pegasys, Hydroxyurea, Pegasys, Hydroxyurea | CONSORZIO MARIO NEGRI SUD, Consorzio Mario Negri Sud, Myeloproliferative Disease Research Consortium (MPD-RC), Myeloproliferative Disorders Research Consortium, National Cancer Institute, F.Hoffmann-La Roche, Cancer Research UK, MPD-RC | The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia vera (PV). | | | | |
NCT01369212: Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 3 | 201 | Canada, US | Tenofovir, Hepatitis B, Viread, Peginterferon-alfa 2a and tenofovir, PEGASYS, tenofovir | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pittsburgh, National Center for Research Resources (NCRR) | Hepatitis B | 03/21 | 03/21 | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir | Eiger BioPharmaceuticals | Hepatitis Delta Virus | 10/22 | 03/23 | | |
